PRESENTATION
Q3 2025 — Results presentation
Q3 2025PDF · 26 pages3.2 MB
Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline. With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, Johnson & Johnson is in a new era of accelerated growth and innovation, with pioneering treatments that will continue to transform lives. 3rd Quarter 2025 Results 3rd Quarter 2025 Sales $24.0B 6.8% Worldwide increased Worldwide increased Excluding the impact of translational currency For full financial data, non-GAAP reconciliations and cautionary statements, please refer to Johnson & Johnson’s earnings release issued on October 14, 2025 available at https://www.investor.jnj.com/financials/quarterly-results/default.aspx 1 Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. 2 Non-GAAP measure; excludes the impact of translational currency. Note: Values may be rounded Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson earnings release issued on October 14, 2025 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. $15.6 billion Worldwide Innovative Medicine sales Innovative Medicine worldwide reported sales increased 6.8% or 5.3% operationally2. Stelara impacted results2 by ~(1,070) basis points. Primary operational drivers: $8.4 billion Worldwide MedTech sales MedTech worldwide reported sales increased 6.8% or 5.6% operationally2 Primary operational drivers: Shockwave Surgical Vision Joaquin Duato Chairman & Chief Executive Officer Johnson & Johnson Wound Closure 5.4%1 Electrophysiology Contact Lenses Adjusted diluted earnings per share1 15.7% $2.80 Worldwide increased Stelara impacted results by ~(640) basis points Diluted earnings per share (EPS) 91.0% $2.12 Worldwide increased Biosurgery Abiomed -- 1 of 26 -- rd October 14, 2025 -- 2 of 26 -- Cautionary note on Forward-looking statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary note on Non-GAAP financial measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website. 3 -- 3 of 26 -- REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology; JNJ-2113 was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize for a broad range of indications Immunology INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL CONSTA developed in collaboration with Alkermes, Inc. Neuroscience PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S. Department of Health and Human Services (HHS) Infectious Diseases INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx Cardiovascular/ Metabolism/Other IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited; AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVANT developed under license with Genmab A/S; LAZCLUZE licensed from Yuhan Corporation; DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; OMT animal platform licensed from OMT Inc. relates to several antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc. Oncology UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan Pulmonary Hypertension Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola was conducted which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center (VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C. Global Public Health Strategic partnerships, collaborations & licensing arrangements During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: 4 -- 4 of 26 -- CEO Remarks Sales performance and earnings review Cash position and guidance update Q&A Agenda 5 John Reed Executive Vice President, Innovative Medicine, R&D Joaquin Duato Chairman and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Darren Snellgrove Vice President, Investor Relations Jennifer Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine Tim Schmid Executive Vice President, Worldwide Chairman, MedTech 1 2 3 4 -- 5 of 26 -- Joaquin Duato Chairman and Chief Executive Officer -- 6 of 26 -- 7 Q3 Earnings summary 1,2 operational sales growth Innovative Medicine MedTech Strong momentum across the business 5.3%1,3 operational sales growth $15 billion+ in quarterly sales for the second time 11 brands growing double digits 5.6%1 operational sales growth 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Includes an approximate (640) basis point headwind from STELARA 3 Includes an approximate (1,070) basis point headwind from STELARA -- 7 of 26 -- Innovative Medicine 8 Oncology Neuroscience Immunology -- 8 of 26 -- MedTech 9 Addressing one of the largest unmet needs in healthcare Advancing the science of surgery and pioneering what's next Developing transformational innovations to improve the health of patients’ eyes Cardiovascular Surgery Vision MedTech Innovation: MedTech Innovation: MedTech Innovation: VARIPULSE Platform Dual Energy THERMOCOOL SMARTTOUCH SF Catheter Shockwave Intravascular Lithotripsy System OMNYPULSE Catheter OTTAVA Robotic Surgical System ETHICON 4000 Surgical Stapler ACUVUE® OASYS 1-Day Family TECNIS Odyssey TECNIS PureSee Impella® Heart Pump Technology -- 9 of 26 -- Johnson & Johnson’s intent to separate its Orthopaedics business -- 10 of 26 -- 11 -- 11 of 26 -- Darren Snellgrove Vice President, Investor Relations -- 12 of 26 -- % Change Q3 2024 Q3 2025 Regional sales results Operational1 Reported 6.2% 6.2% $12.9 $13.7 U.S. 4.4 10.7 4.9 5.4 Europe 7.3 4.9 1.2 1.2 Western Hemisphere (ex U.S.) 3.4 4.0 3.5 3.6 Asia-Pacific, Africa 4.4 7.6 9.6 10.3 International 5.4% 6.8% $22.5 $24.0 Worldwide (WW) Dollars in billions 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded 3rd Quarter 2025 sales 13 -- 13 of 26 -- $24.0 $22.5 $6.8 $5.9 15.7%; 12.4%1 $2.80 $2.42 Dollars in billions, except EPS Reported %; Operational %1 Sales Adjusted earnings2 Adjusted EPS2 6.8%; 5.4%1 GAAP earnings $5.2 $2.7 15.7% Q3 2025 Q3 2024 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 3rd Quarter 2025 financial highlights GAAP EPS 14 Q3 2025 Q3 2024 Q3 2025 Q3 2024 Q3 2025 Q3 2024 Q3 2025 Q3 2024 $2.12 $1.11 91.2% 91.0% -- 14 of 26 -- Immunology $4,168 Infectious Diseases $829 Neuroscience $2,024 Oncology $6,529 CVM/Other $899 PH $1,115 ■ Reported growth ■ Operational growth1 $15,563 6.8%, 5.3% WW sales $MM Key drivers of operational performance1 • DARZALEX increase driven by continued strong share gains and market growth • ERLEADA increase driven by market growth and continued share gains, partially offset by the impact of Part D redesign • CARVYKTI increase driven by continued share gains and site expansion • TECVAYLI and TALVEY growth driven by ongoing launches and continued share gains • RYBREVANT/LAZCLUZE growth driven by ongoing launch and share gains • Growth partially offset by ZYTIGA loss of exclusivity and IMBRUVICA due to competitive pressures and the impact of Part D redesign Oncology • TREMFYA increase due to share gains and market growth, partially offset by unfavorable patient mix and the impact of Part D redesign • SIMPONI/SIMPONI ARIA growth driven mainly by MSD3 return of rights in Europe • REMICADE increase due to a one-time favorable patient mix adjustment and MSD3 return of rights in Europe • STELARA decline driven by the impact of biosimilar competition and Part D redesign Immunology • SPRAVATO growth driven by continued increased physician and patient demand • CAPLYTA acquired April 2, 2025 • INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA decline primarily driven by the impact of Part D redesign Neuroscience • UPTRAVI increase driven by market growth and inventory dynamics, partially offset by the impact of Part D redesign • OPSUMIT/OPSYNVI decline driven by the impact of Part D redesign and unfavorable patient mix, partially offset by share gains and market growth Pulmonary Hypertension (PH) • Declines across the portfolio partially offset by EDURANT growth Infectious Diseases • XARELTO growth driven by the impact of Part D redesign, partially offset by continued share loss Cardiovascular / Metabolism / Other (CVM/Other) Adjusted operational sales2: WW: 3.7%, U.S. 3.3%, Int’l 4.3% Innovative Medicine highlights – 3rd quarter 2025 WW 6.8%, U.S. 6.0%, Int’l 7.9% Reported: WW 5.3%, U.S. 6.0%, Int’l 4.3% Operational1: 1.7%, 1.2% 1.1%, 0.4% 21.3%, 19.2% (0.9)%, (4.3)% (9.8)%, (10.6)% Strong operational growth1 of 5.3% driven primarily by Oncology and Neuroscience 15.3%, 14.6% 15 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 3 MSD: Merck, Sharp, & Dohme 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded Stelara impacted results1 by ~(1,070) basis points -- 15 of 26 -- Key drivers of operational performance1 • Electrophysiology3: Growth driven by procedure growth, commercial execution, new product performance (VARIPULSE, TRUPLUSE), strength in mapping, and one-time impacts of installation and inventory, partially offset by competitive pressures in PFA • Abiomed: Double digit growth driven by continued strong adoption of Impella 5.5 and Impella CP • Shockwave: Double digit growth driven by Coronary and Peripheral portfolios Cardiovascular All platforms impacted by revenue disruption from the previously announced Orthopaedics transformation: • Hips3: Increase driven by new product launches (EMPHASYS) • Trauma3: Growth driven by recently launched products (VOLT) partially offset by trade inventory dynamics and volume-based procurement (VBP) in China • Knees3: Increase driven by strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solutions, partially offset by trade inventory dynamics and VBP in China • Spine, Sports & Other3: Reflects competitive pressures and price pressures in the U.S. Early Interventional segment, partially offset by U.S. spine new product innovations (TriAltis) • Spine: ~ -3% WW, ~ +1% U.S., ~ -9% Int’l Orthopaedics • Advanced3 • Biosurgery: ~ +9% growth driven by continued strength of the portfolio and commercial execution, partially offset by VBP in China • Endocutters: ~ +3% increase primarily due to commercial execution and new products, partially offset by VBP in China and competitive pressures • Energy: ~ -1% due to competitive pressures, Harmonic market decline in the U.S., and VBP in China, partially offset by go-to-market changes in EMEA • General3: Growth primarily due to technology penetration and upgrades within our differentiated Wound Closure portfolio (Barbed & PLUS Sutures) coupled with commercial execution, partially offset by softness in OUS aesthetics Surgery • Contact Lenses/Other: Increase driven by market growth, strong performance of the ACUVUE OASYS 1-Day family, and continued strategic price actions • Surgical: Growth driven by strength of recent product innovations (TECNIS PureSee, TECNIS Odyssey, TECNIS Eyhance), robust demand, and strong commercial execution Vision Adjusted operational sales2: WW 5.7%, U.S. 6.8%, Int’l 4.6% Orthopaedics $2,274 Surgery $2,542 Vision $1,400 Cardiovascular $2,213 ■ Reported growth ■ Operational growth1 $8,430 6.8%, 5.6% WW sales $MM Strong operational growth1 of 5.6% due to Cardiovascular, commercial execution, and innovation WW 6.8%, U.S. 6.6%, Int’l 7.0% Reported: WW 5.6%, U.S. 6.6%, Int’l 4.5% Operational1: 12.6%, 11.6% 7.7%, 6.1% 3.8%, 2.4% 4.4%, 3.3% MedTech highlights – 3rd quarter 2025 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 3 Platforms positively impacted by a one-time reserve adjustment 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded 16 -- 16 of 26 -- % Increase (Decrease) 2024 2025 % to Sales Amount % to Sales Amount 6.8 100.0 $22,471 100.0 $23,993 Sales to customers 4.9 31.0 6,963 30.4 7,303 Cost of products sold 7.6 69.0 15,508 69.6 16,690 Gross Profit 8.1 24.3 5,478 24.7 5,922 Selling, marketing and administrative expenses (25.8) 22.0 4,952 15.3 3,672 Research and development expense (0.4) (99) 0.1 18 Interest (income) expense, net 8.0 1,798 (2.0) (478) Other (income) expense, net 0.2 41 0.3 63 Restructuring 124.5 14.9 3,338 31.2 7,493 Earnings before provision for taxes on income 263.5 2.9 644 9.7 2,341 Provision for taxes on income 91.2 12.0 $2,694 21.5 $5,152 Net Earnings - 91.0 $1.11 $2.12 Net earnings per share (Diluted) 2,427.9 2,428.6 Average shares outstanding (Diluted) 19.3% 31.2% Effective tax rate . Adjusted earnings before provision for taxes and net earnings1 15.9 32.4 $7,277 35.2 $8,436 Earnings before provision for taxes on income 15.7 26.1 $5,876 28.3 $6,801 Net earnings 15.7 $2.42 $2.80 Net earnings per share (Diluted) 19.3% 19.4% Effective tax rate 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website (Unaudited; Dollar and shares in millions except per share figures) 17 3rd Quarter 2025 Condensed consolidated statement of earnings -- 17 of 26 -- % Increase (Decrease) 2024 2025 Innovative Medicine % to Sales Amount % to Sales Amount 6.8 100.0 $14,580 100.0 $15,563 Sales to customers 8.5 19.6 2,852 19.9 3,093 Cost of products sold 6.3 80.4 $11,728 80.1 $12,470 Gross Profit 15.2 17.0 2,491 18.4 2,869 Selling, marketing and administrative expenses (30.1) 28.9 4,211 18.9 2,944 Research and development expense 1 (3.4) (495) (1.5) (238) Other segment items 2 24.9 37.9 $5,521 44.3 $6,895 Adjusted segment income before tax 3 (Unaudited; Dollar in millions) Adjusted earnings before provision for taxes on income by segment 18 % Increase (Decrease) 2024 2025 MedTech % to Sales Amount % to Sales Amount 6.8 100.0 $7,891 100.0 $8,430 Sales to customers 14.4 34.5 2,727 37.0 3,119 Cost of products sold 2.8 65.5 $5,164 63.0 $5,311 Gross Profit 3.0 34.5 2,720 33.2 2,801 Selling, marketing and administrative expenses 6.4 8.7 684 8.6 728 Research and development expense (1.8) (141) 0.2 15 Other segment items 2 (7.0) 24.1 $1,901 21.0 $1,767 Adjusted segment income before tax 3 % Increase (Decrease) 2024 2025 Enterprise % to Sales Amount % to Sales Amount 15.9 32.4 $7,277 35.2 $8,436 Adjusted segment income before tax 3 3rd Quarter 2025 1 Includes acquired IPR&D for the global rights to the NM26 bispecific antibody in Q3 2024, totaling $1,250 2 Other segment items for each reportable segment include charges related to other income and expenses 3 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the company's website -- 18 of 26 -- Joseph J. Wolk Executive Vice President, Chief Financial Officer -- 19 of 26 -- Capital allocation Organic growth business needs Free cash flow1 Priorities are clear and remain unchanged Competitive dividends Share repurchases Higher priority Lower priority Investment in M&A Q3 2025 Dollars in billions ~$19 Cash and marketable securities ~($46) Debt ~($27) Net debt ~$14 Free cash flow1,2 Q3 2025: $3.7B invested in R&D $10.4B year-to-date $3.1B in dividends paid to shareholders; $9.3B year-to-date Note: Values may be rounded 1 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment 2 Estimated as of October 14, 2025. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings Note: Values may be rounded Capital allocation strategy 20 -- 20 of 26 -- Intent to separate our Orthopaedics business Separation expected to take ~18-24 months Represents best path forward for all stakeholders Positions DePuy Synthes for long-term success Further strengthens focus of J&J as an innovation powerhouse 21 -- 21 of 26 -- Increasing operational2 sales guidance to 5.1% and maintaining adjusted operational EPS2,4 at 7.0% (midpoints) Comments July 2025 October 2025 Increasing midpoint to 3.8% 3.2% - 3.7% 3.5% - 4.0% Adjusted operational sales1,2,6 Increasing midpoint by $0.3B to 5.1% $92.7B - $93.1B 4.5% - 5.0% $93.0B - $93.4B 4.8% - 5.3% Operational sales2,6 Increasing midpoint by $0.3B to 5.7% $93.2B - $93.6B 5.1% - 5.6% $93.5B - $93.9B 5.4% - 5.9% Estimated reported sales 3,6 Maintaining Increase of ~300 bps Increase of ~300 bps Adjusted pre-tax operating margin4,5 Increasing $1.0 - $1.2 billion $1.1 - $1.3 billion Net other income4 Tightening range due to higher cash balances $0 - $100 million $0 - $50 million Net interest expense / (income) Increasing due to recently enacted One Big Beautiful Bill Act 17.0% - 17.5% 17.5% - 18.0% Effective tax rate4 Maintaining $10.63 - $10.73 6.5% - 7.5% $10.63 - $10.73 6.5% - 7.5% Adjusted EPS (operational)2,4 Maintaining $10.80 - $10.90 8.2% - 9.2% $10.80 - $10.90 8.2% - 9.2% Adjusted EPS (reported)3,4 2025 P&L guidance 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items 2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses 3 Euro Average Rate: October 2025 = $1.13; Euro Spot Rate: October 2025 = $1.17 6 Excludes COVID-19 Vaccine Note: Values may be rounded 22 -- 22 of 26 -- Innovative Medicine • Accelerating sales growth driven by in-market brands and continued progress from recently launched products • Regarding STELARA, HUMIRA erosion curve remains the best proxy1 • Icotrokinra approval expected • Accelerating sales growth driven by our continued focus on higher-growth markets • Anticipate continued adoption of newer products as well as new planned launches in 2026 • OTTAVA de Novo submission expected 2026 Considerations MedTech • Expect adjusted earnings per share growth is commensurate with sales growth • Reflects our understanding of the present legislative landscape • Includes current expectations for tariffs, foreign exchange rates, and procedural volumes P&L 23 1 Once faced with material biosimilar competition, with the additive impact of Part D re-design -- 23 of 26 -- Q&A John Reed Executive Vice President, Innovative Medicine, R&D Joaquin Duato Chairman and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Darren Snellgrove Vice President, Investor Relations Jennifer Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine Tim Schmid Executive Vice President, Worldwide Chairman, MedTech -- 24 of 26 -- Slide footer goes here if required 25 -- 25 of 26 -- POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA PRESENTATIONS¹ Phase III Phase I/ II P US SIMPONI (golimumab) P US IMAAVY (nipocalimab ) US nipocalimab P US INLEXZO (gemcitabine intravesical system) P AKEEGA (niraparib/abiraterone) P INLEXZO (gemcitabine intravesical system) EU Pediatric Ulcerative Colitis (PURSUIT 2) EU Generalized Myasthenia Gravis (Vivacity MG3) Warm Autoimmune Hemolytic Anemia (ENERGY) Non Muscle Invasive Bladder Cancer (SunRISe-1) M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE) Non Muscle Invasive Bladder Cancer (SunRISe-1) STELARA (ustekinumab) P US SPRAVATO (esketamine) TREMFYA (guselkumab) P US AKEEGA (niraparib/abiraterone) P RYBREVANT / LAZCLUZE RYBREVANT (amivantamab) P EU Pediatric Crohn's Disease (UNITI JR) Treatment Resistant Depression monotherapy (TRD4005) P EU Ulcerative Colitis Subcutaneous Induction (ASTRO) P EU M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE) Non Small Cell Lung Cancer (MARIPOSA Final OS) Head and Neck Cancer (ORIGAMI-4) P US TREMFYA (guselkumab) US CAPLYTA (lumateperone) P US TREMFYA (guselkumab) P TREMFYA (guselkumab) P TALVEY + TECVAYLI Ulcerative Colitis Subcutaneous Induction (ASTRO) Adjunctive Treatment for Major Depressive Disorder Psoriatic Arthritis Structural Damage (APEX) Ulcerative Colitis Subcutaneous Induction (ASTRO) Multiple Myeloma Relapsed/Refractory (RedirecTT-1) P US TREMFYA (guselkumab) US DARZALEX (daratumumab) TREMFYA (guselkumab) P TREMFYA (guselkumab) P JNJ-4496 P EU Crohn's Disease Subcutaneous Induction (GRAVITI) P EU Smoldering Multiple Myeloma (AQUILA) P EU Pediatric Psoriasis (PROTOSTAR) Psoriatic Arthritis Structural Damage (APEX) Hematological Malignancies (LYM1001) P US TREMFYA (guselkumab) US DARZALEX (daratumumab) US STELARA (ustekinumab) P TREMFYA (guselkumab) P JNJ-5322 Pediatric Psoriasis (PROTOSTAR) P EU Frontline multiple myeloma transplant ineligible (CEPHEUS) EU Pediatric Ulcerative Colitis (UNIFI JR) Pediatric Psoriasis (PROTOSTAR) Multiple Myeloma (MMY1001) P US TREMFYA (guselkumab) P US INLEXZO (gemcitabine intravesical system) P US STELARA (ustekinumab) P icotrokinra P RYBREVANT (amivantamab) Pediatric Juvenile Psoriatic Arthritis Non Muscle Invasive Bladder Cancer (SunRISe-1) Pediatric Crohn's Disease (UNITI JR) Psoriasis (ICONIC-LEAD) Colorectal Cancer (ORIGAMI-1 right- sided) P US TREMFYA (guselkumab) US RYBREVANT (amivantamab) P US icotrokinra P icotrokinra P JNJ-8343 P EU Crohn's Disease (GALAXI) P EU Subcutaneous (PALOMA-3) P EU Psoriasis (ICONIC) Psoriasis (ICONIC-TOTAL) Prostate Cancer (PCR1001) TREMFYA (guselkumab) IMBRUVICA (ibrutinib) P icotrokinra JNJ-4804 Co-antibody Therapy P EU Ulcerative Colitis (QUASAR) EU Frontline MCL (Triangle) Psoriasis (ICONIC-Advance1/2) Psoriatic Arthritis (AFFINITY) P US IMAAVY (nipocalimab ) P aticaprant P icotrokinra Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG) Adjunctive Treatment for Major Depressive Disorder with Anhedonia (Ventura 1) Ulcerative Colitis (ANTHEM) P RPGR Gene Therapy nipocalimab Combination Therapy Retinitis Pigmentosa (LUMEOS) Rheumatoid Arthritis (DAISY) Johnson & Johnson Innovative Medicine Pipeline Key Events in 2025* 1. In order to be on key events clinical presentation, data must be presented at a major medical meeting. *This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of October 14, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. = Achieved -- 26 of 26 --